Molecular Pathogenesis of Myeloproliferative Neoplasms

[1] Mullally A(2010)Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells Cancer Cell 17 584-596

[2] Lane SW(2018)Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage Blood 131 649-661

[3] Ball B(2021)Clonal independence of JAK2 and CALR or MPL mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing Haematologica 106 313-315

[4] Megerdichian C(2005)A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 434 1144-1148

[5] Okabe R(2005)Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 365 1054-1061

[6] Al-Shahrour F(2002)Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera Exp Hematol 30 229-236

[7] Li J(2005)Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Cancer Cell 7 387-397

[8] Prins D(2007)JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis N Engl J Med 356 459-468

[9] Park HJ(2008)The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes Blood 111 3751-3759

[10] Grinfeld J(2017)Targeting cell non-autonomous MAPK activation as a novel therapeutic strategy in myeloproliferative neoplasms Blood 130 381-1241

[1] Mullally A(2010)Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells Cancer Cell 17 584-596

[2] Lane SW(2018)Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage Blood 131 649-661

[3] Ball B(2021)Clonal independence of JAK2 and CALR or MPL mutations in comutated myeloproliferative neoplasms demonstrated by single cell DNA sequencing Haematologica 106 313-315

[4] Megerdichian C(2005)A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 434 1144-1148

[5] Okabe R(2005)Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 365 1054-1061

[6] Al-Shahrour F(2002)Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera Exp Hematol 30 229-236

[7] Li J(2005)Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Cancer Cell 7 387-397

[8] Prins D(2007)JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis N Engl J Med 356 459-468

[9] Park HJ(2008)The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes Blood 111 3751-3759

[10] Grinfeld J(2017)Targeting cell non-autonomous MAPK activation as a novel therapeutic strategy in myeloproliferative neoplasms Blood 130 381-1241